Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914244619> ?p ?o ?g. }
- W2914244619 endingPage "718" @default.
- W2914244619 startingPage "709" @default.
- W2914244619 abstract "Abstract Background An increasing number of breast cancer (BC) survivors are at risk of developing contralateral breast cancer (CBC). We aimed to investigate the influence of various adjuvant systemic regimens on, subtype-specific, risk of CBC. Methods This population-based cohort study included female patients diagnosed with first invasive BC between 2003 and 2010; follow-up was complete until 2016. Clinico-pathological data were obtained from the Netherlands Cancer Registry and additional data on receptor status through linkage with PALGA: the Dutch Pathology Registry. Cumulative incidences (death and distant metastases as competing risk) and hazard ratios (HRs) were estimated for all invasive metachronous CBC and CBC subtypes. Results Of 83 144 BC patients, 2816 developed a CBC; the 10-year cumulative incidence was 3.8% (95% confidence interval [CI] = 3.7% to 4.0%). Overall, adjuvant chemotherapy (HR = 0.70, 95% CI = 0.62 to 0.80), endocrine therapy (HR = 0.46, 95% CI = 0.41 to 0.52), and trastuzumab with chemotherapy (HR = 0.57, 95% CI = 0.45 to 0.73) were strongly associated with a reduced CBC risk. Specifically, taxane-containing chemotherapy (HR = 0.48, 95% CI = 0.36 to 0.62) and aromatase inhibitors (HR = 0.32, 95% CI = 0.23 to 0.44) were associated with a large CBC risk reduction. More detailed analyses showed that endocrine therapy statistically significantly decreased the risk of estrogen receptor (ER)-positive CBC (HR = 0.41, 95% CI = 0.36 to 0.47) but not ER-negative CBC (HR = 1.32, 95% CI = 0.90 to 1.93) compared with no endocrine therapy. Patients receiving chemotherapy for ER-negative first BC had a higher risk of ER-negative CBC from 5 years of follow-up (HR = 2.84, 95% CI = 1.62 to 4.99) compared with patients not receiving chemotherapy for ER-negative first BC. Conclusion Endocrine therapy, chemotherapy, as well as trastuzumab with chemotherapy reduce CBC risk. However, each adjuvant therapy regimen had a different impact on the CBC subtype distribution. Taxane-containing chemotherapy and aromatase inhibitors were associated with the largest CBC risk reduction." @default.
- W2914244619 created "2019-02-21" @default.
- W2914244619 creator A5000718039 @default.
- W2914244619 creator A5002482838 @default.
- W2914244619 creator A5007165972 @default.
- W2914244619 creator A5010752349 @default.
- W2914244619 creator A5012843588 @default.
- W2914244619 creator A5016117849 @default.
- W2914244619 creator A5030601121 @default.
- W2914244619 creator A5048535376 @default.
- W2914244619 creator A5063917865 @default.
- W2914244619 creator A5064737301 @default.
- W2914244619 creator A5075329771 @default.
- W2914244619 creator A5076407830 @default.
- W2914244619 date "2019-01-30" @default.
- W2914244619 modified "2023-10-11" @default.
- W2914244619 title "The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype" @default.
- W2914244619 cites W1262485082 @default.
- W2914244619 cites W1562190372 @default.
- W2914244619 cites W1902892164 @default.
- W2914244619 cites W1930652016 @default.
- W2914244619 cites W1972823167 @default.
- W2914244619 cites W1985213644 @default.
- W2914244619 cites W1988262403 @default.
- W2914244619 cites W2000302807 @default.
- W2914244619 cites W2002669739 @default.
- W2914244619 cites W2013827712 @default.
- W2914244619 cites W2014088170 @default.
- W2914244619 cites W2022727635 @default.
- W2914244619 cites W2042752971 @default.
- W2914244619 cites W2043666931 @default.
- W2914244619 cites W2054015138 @default.
- W2914244619 cites W2056696144 @default.
- W2914244619 cites W2062672427 @default.
- W2914244619 cites W2065924918 @default.
- W2914244619 cites W2071658354 @default.
- W2914244619 cites W2073129224 @default.
- W2914244619 cites W2096366696 @default.
- W2914244619 cites W2098942227 @default.
- W2914244619 cites W2107011655 @default.
- W2914244619 cites W2108527123 @default.
- W2914244619 cites W2115432999 @default.
- W2914244619 cites W2118728607 @default.
- W2914244619 cites W2119632042 @default.
- W2914244619 cites W2122589024 @default.
- W2914244619 cites W2129298960 @default.
- W2914244619 cites W2139658581 @default.
- W2914244619 cites W2148339479 @default.
- W2914244619 cites W2159752027 @default.
- W2914244619 cites W2161864293 @default.
- W2914244619 cites W2164353984 @default.
- W2914244619 cites W2198590456 @default.
- W2914244619 cites W2218994245 @default.
- W2914244619 cites W2254261888 @default.
- W2914244619 cites W2316025483 @default.
- W2914244619 cites W2341475839 @default.
- W2914244619 cites W2410121552 @default.
- W2914244619 cites W2466633991 @default.
- W2914244619 cites W2528054285 @default.
- W2914244619 cites W2605630208 @default.
- W2914244619 doi "https://doi.org/10.1093/jnci/djz010" @default.
- W2914244619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30698719" @default.
- W2914244619 hasPublicationYear "2019" @default.
- W2914244619 type Work @default.
- W2914244619 sameAs 2914244619 @default.
- W2914244619 citedByCount "38" @default.
- W2914244619 countsByYear W29142446192019 @default.
- W2914244619 countsByYear W29142446192020 @default.
- W2914244619 countsByYear W29142446192021 @default.
- W2914244619 countsByYear W29142446192022 @default.
- W2914244619 countsByYear W29142446192023 @default.
- W2914244619 crossrefType "journal-article" @default.
- W2914244619 hasAuthorship W2914244619A5000718039 @default.
- W2914244619 hasAuthorship W2914244619A5002482838 @default.
- W2914244619 hasAuthorship W2914244619A5007165972 @default.
- W2914244619 hasAuthorship W2914244619A5010752349 @default.
- W2914244619 hasAuthorship W2914244619A5012843588 @default.
- W2914244619 hasAuthorship W2914244619A5016117849 @default.
- W2914244619 hasAuthorship W2914244619A5030601121 @default.
- W2914244619 hasAuthorship W2914244619A5048535376 @default.
- W2914244619 hasAuthorship W2914244619A5063917865 @default.
- W2914244619 hasAuthorship W2914244619A5064737301 @default.
- W2914244619 hasAuthorship W2914244619A5075329771 @default.
- W2914244619 hasAuthorship W2914244619A5076407830 @default.
- W2914244619 hasBestOaLocation W29142446192 @default.
- W2914244619 hasConcept C121608353 @default.
- W2914244619 hasConcept C126322002 @default.
- W2914244619 hasConcept C143998085 @default.
- W2914244619 hasConcept C207103383 @default.
- W2914244619 hasConcept C2908647359 @default.
- W2914244619 hasConcept C44249647 @default.
- W2914244619 hasConcept C50382708 @default.
- W2914244619 hasConcept C530470458 @default.
- W2914244619 hasConcept C71924100 @default.
- W2914244619 hasConcept C72563966 @default.
- W2914244619 hasConcept C88879693 @default.
- W2914244619 hasConcept C90924648 @default.
- W2914244619 hasConcept C99454951 @default.